The bilayer heterojunction devices were fabricated successfully by using a novel oxadiazole derivative:2,2-(2,5-thiophenediyl)bis(5-(4-methyl)phenyl-1,3,4-oxadiazole)(T-OXD)as the electron-transporting layer(ETL)and a...The bilayer heterojunction devices were fabricated successfully by using a novel oxadiazole derivative:2,2-(2,5-thiophenediyl)bis(5-(4-methyl)phenyl-1,3,4-oxadiazole)(T-OXD)as the electron-transporting layer(ETL)and a pyrazoline derivative:1-phenyl-3-(dimethylamino)styryl-5-(p-(dimethylamino)phenyl)pyrazoline(PDP)as the light-emitting layer and the hole-transporting layer.The emission at 500nm was derived from PDP layer.In comparison with the bilayer device of tris(8-hydroxyquinoline)aluminum(Alq)as the ETL,the luminous efficiency of the PDP/T-OXD heterojunction device was enhanced by 104 times.展开更多
T Objective： To evaluate the therapeutic efficacy and side effects of oral Fructus bruceae oil combined with radiotherapy in the treatment of esophageal cancer. Methods： A total of 80 patients with esophageal cancer...T Objective： To evaluate the therapeutic efficacy and side effects of oral Fructus bruceae oil combined with radiotherapy in the treatment of esophageal cancer. Methods： A total of 80 patients with esophageal cancer were equally and randomly divided into two groups. The patients in Group A were treated with radiotherapy （60-65 Gy, 6-7 weeks） and oral Fructus bruceae oil （20 mL, 3 times per day for 12 weeks）, while the patients in Group B were treated with radiotherapy alone. The short-term effect was evaluated by Response Evaluation Criteria in Solid Tumors （RECIST） and quality of life （QOL） was evaluated by the Kamofsky scoring （KFS）. The outcome measures included complete remission （CR） rate, partial remission （PR） rate, effective rate as CR＋PR, patients＇ QOL and adverse effects. Results： After 12-week treatment, the CR and CR＋PR were significantly higher in Group A than those in Group B （P〈0.05）. There was an improvement in esophageal obstruction of 67.5% and 60.0%, respectively, and in KFS of 84.6% and 43.9%, respectively, in Groups A and B. Conclusion： Oral medication with oral Fructus bruceae oil could effectively improve the efficacy of radiotherapy in esophageal cancer, including a reduction in esophageal obstruction, and also reduce the side effects of radiotherapy; thus it would be very promising for clinical application.展开更多
基金Supported by the National Natural Science Foundation of China under Grant No.597905006。
文摘The bilayer heterojunction devices were fabricated successfully by using a novel oxadiazole derivative:2,2-(2,5-thiophenediyl)bis(5-(4-methyl)phenyl-1,3,4-oxadiazole)(T-OXD)as the electron-transporting layer(ETL)and a pyrazoline derivative:1-phenyl-3-(dimethylamino)styryl-5-(p-(dimethylamino)phenyl)pyrazoline(PDP)as the light-emitting layer and the hole-transporting layer.The emission at 500nm was derived from PDP layer.In comparison with the bilayer device of tris(8-hydroxyquinoline)aluminum(Alq)as the ETL,the luminous efficiency of the PDP/T-OXD heterojunction device was enhanced by 104 times.
基金Projects(51535012,U1604255)supported by the National Natural Science Foundation of ChinaProject(2016JC2001)supported by the Key Research and Development Project of Hunan Province,China
基金Supported by the Science-and Technology Plan, Development and Support Projects of Zhengzhou City （No. 0910SGYS33377-1 ）
文摘T Objective： To evaluate the therapeutic efficacy and side effects of oral Fructus bruceae oil combined with radiotherapy in the treatment of esophageal cancer. Methods： A total of 80 patients with esophageal cancer were equally and randomly divided into two groups. The patients in Group A were treated with radiotherapy （60-65 Gy, 6-7 weeks） and oral Fructus bruceae oil （20 mL, 3 times per day for 12 weeks）, while the patients in Group B were treated with radiotherapy alone. The short-term effect was evaluated by Response Evaluation Criteria in Solid Tumors （RECIST） and quality of life （QOL） was evaluated by the Kamofsky scoring （KFS）. The outcome measures included complete remission （CR） rate, partial remission （PR） rate, effective rate as CR＋PR, patients＇ QOL and adverse effects. Results： After 12-week treatment, the CR and CR＋PR were significantly higher in Group A than those in Group B （P〈0.05）. There was an improvement in esophageal obstruction of 67.5% and 60.0%, respectively, and in KFS of 84.6% and 43.9%, respectively, in Groups A and B. Conclusion： Oral medication with oral Fructus bruceae oil could effectively improve the efficacy of radiotherapy in esophageal cancer, including a reduction in esophageal obstruction, and also reduce the side effects of radiotherapy; thus it would be very promising for clinical application.
